Fable Therapeutics, a discovery-stage biotechnology company developing purpose-built biologics powered by state-of-the-art structure and sequence-based protein language models, announced the appointment of David J. Baker, PhD, as Chief Scientific Officer (CSO).
“David’s extensive experience in drug discovery, with a strong track record of high performance and scientific leadership across the cardio-metabolic therapeutic area, makes him an ideal leader to advance our portfolio,” said Geoff MacKay, President & CEO of Fable. “We are excited to welcome David to our leadership team and for him to guide Fable’s scientific strategy and innovative platform.”
Dr. Baker contributes deep expertise leading highly successful teams from across industry and academia. Prior to joining Fable, Dr. Baker was Head of Metabolism Bioscience for Cardiovascular, Renal and Metabolism (CVRM) at AstraZeneca plc. He was responsible for guiding the metabolism portfolio from target selection to Ph2b in diabetes, obesity, MASH and dyslipidemia.
Also Read: Aitia and Gustave Roussy Join Forces to Identify the Fundamental Biological Causes of Multiple Human Cancers
Dr. Baker joins Fable at a pivotal time to oversee the company’s scientific strategy from discovery through to IND and first-in-human studies. “I’m thrilled to be joining such a groundbreaking company with extremely talented individuals and looking forward to bringing new therapies to patients,” said Dr. Baker.
SOURCE: Businesswire